ALL enters the final two weeks before its July 29 earnings report with the Street divided — UBS just stepped to the sidelines while JP Morgan raised its target to a new high, and options traders are sitting at the most defensive reading of the past year.
The analyst picture shifted meaningfully this week. UBS downgraded ALL to Neutral on Tuesday, even while lifting its price target to $261 — a classic "upgrading the valuation, downgrading the conviction" move that signals the easy money on this run may be spent. That cuts against JP Morgan, which held its Overweight rating and bumped its target from $263 to $282 on Monday. The broader direction across the past ten days has been constructive: Mizuho, Raymond James, and Evercore ISI all raised targets, with Raymond James running the most bullish at $300. The mean consensus price target of $253 now sits within striking distance of the $250.35 close, leaving implied upside narrow and the rating mix at a cautious hold — 8 buys, 13 holds, and the Barclays Underweight at $213 anchoring the bear side.
Options positioning has reached an extreme that is harder to dismiss than the analyst churn. The put/call ratio climbed to 1.50 on Tuesday — the highest reading of the past 52 weeks, up from a mid-June range of around 1.08 to 1.12, and nearly 1.5 standard deviations above its 20-day average of 1.25. That is a decisive tilt toward downside protection, not routine hedging. The PCR has now stayed elevated for a full week, suggesting this is not one-day noise ahead of a single event but a sustained positioning shift as the July 29 print approaches. The prior note flagged the options signal as the sharpest data point a week ago; it has only intensified since.
The short side, by contrast, remains quiet. SI runs at 3.2% of free float — unchanged from last week's reading — and has drifted roughly 3% lower over the month. Borrow is cheap at 0.50%, ticking up slightly on the week but still well inside normal ranges. Availability is exceptionally deep at nearly 1,494% of short interest, far from any squeeze pressure. The short score of 39.8 is in the lower third of its recent range, consistent with a stock where active shorts see limited edge. None of this changes the pre-earnings narrative — it simply confirms that whatever caution exists is concentrated in options, not in the lending market.
The sector backdrop adds context to the week's 2.4% single-day slip. PGR fell 3.4% on the day, CB dropped 2.4%, and TRV shed 1.4% — so ALL's Tuesday decline was broad sector weakness rather than stock-specific pressure. ALL is still up nearly 13% over the past month, a run that has left valuation multiples higher: the price-to-book has expanded 0.22x over 30 days to 1.79x, and the trailing PE has moved up by roughly 1.2x turns to 8.6x. Both remain undemanding in absolute terms, but the expansion is coming at a moment when the UBS downgrade explicitly flags limited room to re-rate higher.
Factor scores add a final note of asymmetry. The EPS surprise rank is strong at the 85th percentile, and 90-day EPS momentum is at the 90th percentile — both pointing to a company that has been beating and revising higher. The 30-day EPS momentum score, however, has fallen to the 10th percentile, and the forward EPS growth rank sits at 18th. That gap between recent beat history and near-term earnings growth expectations is precisely the kind of setup that makes pre-earnings options markets nervous, and the PCR at its 52-week high says investors are paying for that asymmetry. The July 29 print will test whether ALL's underwriting momentum can keep pace with a stock that has already moved a long way.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Allstate heads into its Q1 2026 earnings print on Thursday with call-side positioning at its most dominant reading in over a year — and the stock up 4.2% on the week to $224.58, already pricing in some optimism before…
Allstate reports Q1 2026 results on May 22 with analysts tilting constructively, even as options traders have quietly shifted to their most bullish posture in months. The most striking signal heading into the print is…
